Oncopeptides Achieves Remarkable Financial Growth and Market Expansion in 2025
Oncopeptides experiences substantial growth and plans for profitability by 2026 amid market expansion.
Key Points
- • 30% growth for three consecutive quarters and 135% year-over-year growth as of Q2 2025.
- • Sales increased by 45% in Q2 compared to the prior quarter, with strong market performance in Germany, Spain, and Italy.
- • CEO Sofia Heigis expects profitability by the end of 2026, supported by a potential market of 1.5 billion SEK.
- • Ongoing development of new drug candidates OPD5 and OPDC3 alongside its main drug Pepaxti.
Oncopeptides, a Swedish biotech company specializing in therapies for challenging cancers, has reported significant financial growth and market expansion in 2025. The company's latest figures reveal over 30% growth for three consecutive quarters and a staggering 135% year-over-year increase as of Q2 2025. CEO Sofia Heigis stated that Oncopeptides is on track to achieve profitability by the end of 2026, driven by robust performance across key European markets.
In Q2 alone, Oncopeptides saw a 45% surge in sales compared to the previous quarter, with a strong presence in Germany, Spain, and Italy. Notably, the company has secured access to 97% of Spanish regions and 80% of Italian regions, exceeding initial expectations. Heigis attributed this growth to effective pricing negotiations and the establishment of dedicated sales teams that work closely with healthcare providers, noting that once doctors prescribe Pepaxti, they tend to continue its use, creating a consistent demand.
To further fuel its expansion, Oncopeptides is conducting a fully guaranteed rights issue aimed at accelerating sales in Europe while investing in its drug pipeline. The company has identified a potential market of approximately 1.5 billion SEK, with its top four markets representing half of this potential.
Additionally, Oncopeptides is in discussions to launch its main drug, Pepaxti, in Japan, with an ongoing approval process in South Korea. Beyond Pepaxti, the company is developing new drug candidates OPD5 and OPDC3 for additional cancer treatments. Heigis expressed optimism that the success of Pepaxti would enhance credibility for the company's future drug developments. Oncopeptides operates from its Stockholm headquarters and has a preclinical drug development facility in Solna.